AE Adverse event ACR Albumin creatinine ratio ACS Acute Coronary Syndrome BARI 2D Bypass Angioplasty Revascularization Investigation 2 Diabetes BID Twice a day BMI Body mass index BP Blood Pressure CABG Coronary artery bypass graft CEC Clinical endpoint committee CEVA Clinical endpoint validation and adjudication CHF Congestive heart failure CMPHU Committee for Medicinal Products for Human Use CI Confidence interval CPMP Committee for Proprietary Medicinal Products CRP C-reactive protein CSR Clinical study report CV Cardiovascular dL Deciliter DCCT Diabetes Control and Complications Trial DM Diabetes mellitus EU European Union EMEA European Medicines Evaluation Agency FDA Food and Drug Administration FPG Fasting plasma glucose GCP Good clinical practice GLIB Glibenclamide (glyburide) GLIC Gliclazide GLIM Glimepiride GLIP Glipizide GLY Glyburide (glibenclamide) GSK GlaxoSmithKline HbA1c Glycated hemoglobin A HCP Healthcare provider HDL-c High density lipoprotein-cholesterol HR Hazard ratio ICH International Conference on Harmonization ICT Integrated clinical trials IDMC Independent Data Monitoring Committee IFG Impaired fasting glucose IGT Impaired glucose tolerance IHD Ischemic heart disease IMT Intimal medial thickness INS Insulin IP Insulin-providing IRB Institutional Review Board IS Insulin-sensitizing ITT Intent-to-treat IVUS Intravascular ultrasonography LOCF Last observation carried forward LDL-c Low density lipoprotein-cholesterol m Meter MACE Major adverse cardiovascular event MCP Monocyte chemoattractant protein MedDRA Medical Dictionary for Regulatory Activities MET Metformin mg Milligram MI Myocardial infarction MOA Mechanism of action MMP matrix metalloproteinase NA Not applicable NHANES National Health and Nutrition Examination Surveys NHLBI National Heart Lung and Blood Institute NIH National Institutes of Health NYHA New York Heart Association OR Odds ratio PAI Plasminogen activator inhibitor PI Package insert or prescribing information PIL Patient information leaflet PIO Pioglitazone PRO Patient-reported outcomes QD Every day (once a day) QOL Quality of life RAMI Ramipril RR Risk ratio RSG Rosiglitazone SAE Serious adverse event SC Subcutaneous SD Standard deviation SU Sulfonylurea SVG Saphenous vein graft T2DM Type 2 diabetes mellitus TIA Transient ischemic attack TID Three times a day TZD Thiazolidinedione U Units UKPDS United Kingdom Prospective Diabetes Study US United States USPI US Prescribing Information VADT Veterans Affairs Diabetes Trial
Get more Avandia Recall News and Avanda Lawsuit Information at AvandiaRecallNews.com.